首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Melanoma management

缩写:

ISSN:2045-0885

e-ISSN:2045-0893

IF/分区:1.1/Q4

文章目录 更多期刊信息

共收录本刊相关文章索引134
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Abby Vrable,Richard Chang Abby Vrable
Primary malignant melanoma originating in the small bowel is very rare. We report the case of primary malignant melanoma of the small bowel with secondary intussusception in a 51-year-old female with no prior history of cutaneous melanoma. ...
Keiran Sm Smalley Keiran Sm Smalley
Dr Smalley earned his PhD in Pharmacology from the University of Cambridge, UK, in 2001. He worked as a post-doctoral fellow in the Oncology Department of University College London, the Institute of Cancer Research, Fulham Road and the Wist...
Imogen Cheese Imogen Cheese
Imogen Cheese speaks to Sebastian Dennis-Beron, Commissioning Editor: Imogen was diagnosed with melanoma in June 2013 (currently stage 2C no evidence of disease monitored under Professor Mark Middleton at Oxford) and has since created and w...
Richard Tyrell,Camila Antia,Sharon Stanley et al. Richard Tyrell et al.
Melanoma is the deadliest form of skin cancer and one of the few malignancies whose incidence is on the rise. The treatment of metastatic melanoma continues to be quite challenging, although in recent years, there has been significant progr...
Madalyn G Neuwirth,Edmund K Bartlett,Giorgos C Karakousis Madalyn G Neuwirth
The extent and timing of regional lymphadenectomy and its role in patients with clinically localized primary melanoma has been the subject of considerable debate. While therapeutic lymphadenectomy for clinically positive nodes is uniformly ...
Hugo Arasanz,Alejandra Lacalle,Maria José Lecumberri et al. Hugo Arasanz et al.
Immunotherapy has radically transformed the management of metastatic malignant melanoma. Ipilimumab, a CTLA-4-targeted monoclonal antibody, was the first immunotherapeutic drug to reach a survival benefit compared with traditional chemother...